Business
Perimeter Medical Imaging AI Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Perimeter Medical Imaging AI Reports Second Quarter 2023 Financial Results and Provides Corporate...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n \n \n \n Perimeter Medical Imaging AI Reports Second Quarter 2023 Financial Results and Provides Corporate Update\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n Conference Call/Webcast Today at\n \n 5 pm ET\n \n \n \n \n \n \n \n TORONTO\n \n and\n \n DALLAS\n \n \n ,\n \n \n Aug. 29, 2023\n \n \n /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) (\"Perimeter\" or the \"Company\") – a commercial-stage medical technology company – today reported financial results for its second quarter ended\n \n June 30, 2023\n \n and provided a corporate update.\n \n \n \n \n Key Highlights\n \n \n \n \n \n Completed a\n \n \n leadership transition\n \n \n with appointment of new CEO and Board member, and expanded its leadership team with appointment of CFO and Chief Innovation Officer\n \n \n \n \n Received regulatory approval to implement a substantially enhanced AI algorithm in the ongoing pivotal clinical trial under the existing study protocol\n \n \n \n \n Initiated additional clinical trial sites at\n \n \n Baptist MD Anderson Cancer Center\n \n \n and Mayo Clinic in\n \n Florida\n \n \n \n \n \n Expanded its customer base with commercial installations of Perimeter's flagship S-Series OCT in the states of\n \n \n \n Utah\n \n \n \n and\n \n \n \n Georgia\n \n \n \n \n \n \n \n Adrian Mendes\n \n , Perimeter's Chief Executive Officer stated, \"I am pleased to report a number of significant developments within the business since joining Perimeter as its CEO this quarter. Concurrent with my appointment, Dr.\n \n Josh Vose\n \n joined our Board of Directors and has provided invaluable insights into our clinical development program. Importantly, we received approval from the FDA to introduce an enhanced AI algorithm in the ongoing clinical trial under the existing study protocol. As a result, all clinical trial sites, including the newest trial site at Mayo Clinic in\n \n Florida\n \n , will use the updated AI as patients continue to enroll in...